Current Liabilities
Deferred Revenue
Alnylam Pharmaceuticals Deferred Revenue decreased by 33.7% to $3.21M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 88.6%, from $28.16M to $3.21M. Over 5 years (FY 2020 to FY 2025), Deferred Revenue shows a downward trend with a -48.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
First reportedQ4 2014
Last reportedQ1 2026Apr 30, 2026
Metric ID:
deferred_revenue_currentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $98.14M | $115.04M | $149.48M | $131.84M | $114.29M | $144.21M | $42.11M | $35.79M | $54.64M | $77.14M | $102.75M | $76.85M | $69.01M | $71.03M | $55.48M | $28.16M | $15.08M | $2.54M | $4.85M | $3.21M |
| QoQ Change | — | +17.2% | +29.9% | -11.8% | -13.3% | +26.2% | -70.8% | -15.0% | +52.6% | +41.2% | +33.2% | -25.2% | -10.2% | +2.9% | -21.9% | -49.2% | -46.4% | -83.1% | +90.7% | -33.7% |
| YoY Change | — | — | — | — | +16.5% | +25.4% | -71.8% | -72.9% | -52.2% | -46.5% | +144.0% | +114.7% | +26.3% | -7.9% | -46.0% | -63.4% | -78.1% | -96.4% | -91.3% | -88.6% |
Range$2.54M – $149.48M
CAGR-51.3%
Avg YoY Growth-24.3%
Median YoY Growth-49.4%
Product Breakdown
| Segment | Q4 '23 | Q2 '24 | Q3 '24 |
|---|---|---|---|
| Roche Development Services Obligation | — | $545.00M | $545.00M |
| Roche License Obligation | — | $375.00M | $375.00M |
| Roche Technology Transfer Obligation | — | $2.00M | $2.00M |
| C5 Co-Co Obligation | $186.20M | — | — |
| C5 License Obligation | $27.50M | — | — |
| Research Services Obligation | $63.40M | — | — |
| Total | $102.75M | $69.01M | $71.03M |
C5 Co-Co Obligation, Roche Development Services Obligation, Roche License Obligation, Roche Technology Transfer Obligation were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Deferred Revenue at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's deferred revenue?
- Alnylam Pharmaceuticals (ALNY) reported deferred revenue of $3.21M in Q1 2026.
- How has Alnylam Pharmaceuticals's deferred revenue changed year-over-year?
- Alnylam Pharmaceuticals's deferred revenue decreased by 88.6% year-over-year, from $28.16M to $3.21M.
- What is the long-term trend for Alnylam Pharmaceuticals's deferred revenue?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's deferred revenue has grown at a -48.0% compound annual growth rate (CAGR), from $127.21M to $4.85M.